The findings held true regardless of patient age, the presence or absence of diabetes, and albuminuria.
This meta-analysis, which was supported by the National Kidney Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases, will result in six publications during the next year. The first was published online on June 3 (JAMA 2014 [doi:10.1001/jama.2014.6634]). The JAMA report goes beyond Dr. Coresh’s time-limited Las Vegas presentation in that it also includes data on all-cause mortality risk according to change in eGFR. He noted this is important because the majority of patients with CKD die of cardiovascular and other causes without ever reaching ESRD. In the meta-analysis, a 30% decline in eGFR over the course of 2 years was associated with an 80% increased risk in all-cause mortality.
Dr. Coresh reported having no relevant financial conflicts.